정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2312 | Not yet recruiting | A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects | COVID-19 | Drug: OT-101 Drug: Artemisinin Drug: Placebo |
Phase 2 | Oncotelic Inc. | INDUSTRY | 18 | All | 18 Years ~ 80 Years | Praxis Pesquisa Medica S / S Ltda, Jardim, Brazil |
| 2311 | Terminated | A Study to Evaluate the Safety and Efficacy of Razuprotafib, a Novel Tie 2 Activator, in Hospitalized Subjects With Moderate to Severe Coronavirus Disease 2019 (COVID-19) | Acute Respiratory Distress Syndrome | Drug: Razuprotafib Subcutaneous Solution Drug: Placebo Subcutaneous Solution |
Phase 2 | Aerpio Therapeutics, Medical Technology Enterprise Consortium (MTEC) | INDUSTRY | 31 | All | 18 Years | University of Southern California, Los Angeles, California, United States University of California- Irvine Medical Center, Orange, California, United States MedStar Georgetown University Hospital, Washington, District of Columbia, United States Snake River Research, Idaho Falls, Idaho, United States University of Minnesota, Minneapolis, Minnesota, United States University of Cincinnati, Cincinnati, Ohio, United States Rhode Island Hospital, Providence, Rhode Island, United States |
| 2310 | Completed | A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia | COVID-19 Pneumonia | Drug: Tocilizumab (TCZ) Drug: Placebo |
Phase 3 | Hoffmann-La Roche | INDUSTRY | 452 | All | 18 Years | University of California San Diego, La Jolla, California, United States eStudySite, La Mesa, California, United States David Geffen School of Medicine UCLA, Los Angeles, California, United States Stanford University, Stanford, California, United States Denver Health Medical Center, Denver, Colorado, United States University of Miami Miller School of Medicine, Miami, Florida, United States Rush University Medical Center, Chicago, Illinois, United States University of Chicago, Chicago, Illinois, United States Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States Baystate Health System, Springfield, Massachusetts, United States Mayo Clinic - PPDS, Rochester, Minnesota, United States Hackensack University Medical Center, Hackensack, New Jersey, United States Robert Wood Johnson University Hospital/Rutgers, New Brunswick, New Jersey, United States James J Peters Veterans Administration Medical Center - NAVREF, Bronx, New York, United States Duke University Medical Center, Durham, North Carolina, United States Cleveland Clinic Foundation; Pulmonary, Allergy & Critical Care Medicine, Cleveland, Ohio, United States Thomas Jefferson University, Philadelphia, Pennsylvania, United States Baylor St. Luke's Medical Center, Houston, Texas, United States Ben Taub General Hospital - HCHD, Houston, Texas, United States Intermountain Medical Group, Saint George, Utah, United States Intermountain LDS Hospital, Salt Lake City, Utah, United States Evergreen Health Infectious Disease, Kirkland, Washington, United States Swedish Hospital Medical Center, Seattle, Washington, United States Hamilton General Hospital; Pharmacy, Hamilton, Ontario, Canada St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada University Health Network, Toronto, Ontario, Canada Clinical Research Institute of Montreal, Montreal, Quebec, Canada Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark Hvidovre Hospital, Hvidovre, Denmark Odense Universitetshospital, Odense C, Denmark Sjællands Universitetshospital, Roskilde, Roskilde, Denmark Centre Hospitalier Departemental de Vendee, La Roche Sur Yon, France Centre Hospitalier et Universitaire de Limoges, Limoges, France Hopital de La Croix Rousse, Lyon, France Hotel Dieu - Nantes, Nantes, France Hopital de la Pitie Salpetriere, Paris, France HOPITAL COCHIN university hospital, Paris, France CHRU de Tours, Pharmacie, Tours, France Universitatsklinikum Dusseldorf, Dusseldorf, Germany Medizinische Hochschule Hannover, Hannover, Germany Universitatsklinikum Koln; Innere Medizin I; Onkologie, Hamatologie, Koln, Germany LMU Klinikum der Universitat Munchen, Munchen, Germany Azienda Ospedaliera San Gerardo di Monza, Monza MI, Lombardia, Italy Fondazione IRCCS Policlinico San Matteo di Pavia; S.S. Fisiopatologia Respiratoria, Pavia, Lombardia, Italy Amphia Ziekenhuis, Breda, Netherlands St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands Erasmus MC, Rotterdam, Netherlands Universitair Medisch Centrum Utrecht, Utrecht, Netherlands Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain Hospital Universitari Vall d'Hebron, Barcelona, Spain Hospital Clinic de Barcelona, Barcelona, Spain Hospital Universitario La Paz, Madrid, Spain Hospital Universitario Ramon y Cajal, Madrid, Spain Hospital General Universitario Gregorio Maranon, Madrid, Spain Hospital Universitario HM Sanchinarro-CIOCC, Madrid, Spain Greater Glasgow and Clyde Health Board, Glasgow, United Kingdom Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom University College Hospital, London, United Kingdom Royal Free Hospital, London, United Kingdom St George's Clinical Research Facility, London, United Kingdom Imperial College London, London, United Kingdom North Manchester General Hospital, Manchester, United Kingdom |
| 2309 | Active, not recruiting | A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine | COVID-19 | Biological: AdimrSC-2f | Phase 1 | Adimmune Corporation | INDUSTRY | 70 | All | 20 Years ~ 60 Years | National Taiwan University Hospital, Taipei, Taiwan |
| 2308 | Active, not recruiting | A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19 | COVID-19 | Biological: MVC-COV1901 | Phase 1 | Medigen Vaccine Biologics Corp. | INDUSTRY | 45 | All | 20 Years ~ 50 Years | National Taiwan University Hospital, Taipei, Taiwan |
| 2307 | Active, not recruiting | A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19 | Severe Acute Respiratory Syndrome | Biological: CVnCoV Vaccine Drug: Placebo |
Phase 3 | CureVac AG, German Federal Ministry of Education and Research | INDUSTRY | 2360 | All | 18 Years | Universitatsmedizin der Johannes Gutenberg-Universitat Mainz Langenbeckstr. 1, Mainz, Germany |
| 2306 | Not yet recruiting | A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine | Coronavirus | Biological: UB-612 Other: Placebo |
Phase 3 | Vaxxinity, Inc., Diagnosticos da America S/A (DASA) | INDUSTRY | 7320 | All | 18 Years |
